Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
David H
DH
Johnson
Carlos L
CL
Arteaga
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D017322:Clinical Trials, Phase II as Topic; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors*; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011799:Quinazolines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate
D000970:Antineoplastic Agents; D011799:Quinazolines; D004815:Epidermal Growth Factor; D000077156:Gefitinib